Statins may improve survival for triple-negative breast cancer patients
A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.
The study, led by Kevin Nead, M.D., assistant...
MD Anderson Research Highlights for July 28, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson and Blueprint Medicines announce strategic collaboration to accelerate BLU-222 development
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year strategic research collaboration...
MD Anderson again ranks No. 1 in cancer by U.S. News & World Report
The University of Texas MD Anderson Cancer Center again has been named No. 1 in cancer in the U.S. News & World Report’s 2021-2022 annual “Best Hospitals” rankings. Since the ranking's inception in 1990, the institution has been selected as one of the top two hospitals for cancer in the country.
“This year’s ranking is especially rewarding considering the exceptional teamwork and collaboration we have seen throughout our...
MD Anderson Research Highlights for July 14, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Atezolizumab and bevacizumab show meaningful responses for malignant peritoneal mesothelioma patients
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab...
Novel immunotherapy combination produces durable response in frontline metastatic melanoma
A Phase II cohort from the international PIVOT-02 study has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin...
MD Anderson and Hummingbird Bioscience announce strategic research collaboration to advance innovative immunotherapies
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience today announced the launch of a multi-year strategic research...
Study identifies gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients
Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade...